Get the Stockscreener App
1.03
0.96%
-0.01
Ovid Therapeutics Inc stock is traded at $1.03, with a volume of 28,044.
It is down -0.96% in the last 24 hours and down -13.45% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
See More
Previous Close:
$1.04
Open:
$1.05
24h Volume:
28,044
Relative Volume:
0.16
Market Cap:
$73.46M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-1.4714
EPS:
-0.7
Net Cash Flow:
$-45.92M
1W Performance:
-10.43%
1M Performance:
-13.45%
6M Performance:
-66.88%
1Y Performance:
-68.60%
1-Day Range:
$1.01
$1.07
1-Week Range:
$0.9877
$1.19
52-Week Range:
$0.68
$4.10
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| OVID | 1.03 | 73.46M | 391.70K | -52.34M | -45.92M | -0.70 |
| VRTX | 447.18 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.71 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.36 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
B. Riley Decreases Earnings Estimates for Ovid Therapeutics - Defense World
Fragile X Syndrome (Fxs) Treatment Market Growth Overview - openPR
Wedbush Forecasts Weaker Earnings for Ovid Therapeutics - Defense World
Equities Analysts Issue Forecasts for OVID FY2024 Earnings - Defense World
William Blair Has Positive Outlook for OVID FY2024 Earnings - MarketBeat
RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters
Ovid Therapeutics Inc (OVID) Quarterly 10-Q Report - Quartzy
William Blair Analysts Increase Earnings Estimates for OVID - MarketBeat
Ovid Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com Canada
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - GlobeNewswire
US Penny Stocks To Watch This November 2024 - Simply Wall St
Ovid Therapeutics to Host Investor Event - GlobeNewswire
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - MarketBeat
Layoff Tracker: Sage Therapeutics Will Lay Off 33% of Employees - BioSpace
Ovid Therapeutics (STU:1OT) Cyclically Adjusted Revenue per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
Ovid Therapeutics (STU:1OT) Revenue per Share : €0.01 (TTM As of Jun. 2024) - GuruFocus.com
Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents 2024 - Legal Service India
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
Marinus Pharmaceuticals' patent upheld by PTAB - Investing.com
Rhumbline Advisers Sells 12,851 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents (2024) - Legal Service India
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright - Investing.com
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? - Yahoo Finance
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID) - Defense World
1,400,191 Shares in Ovid Therapeutics Inc. (NASDAQ:OVID) Bought by Driehaus Capital Management LLC - MarketBeat
Ovid stock gets boost from promising OV329 toxicity profileB.Riley - Investing.com
Ovid reports promising safety profile for epilepsy drug OV329 - Investing.com
Ovid Therapeutics Presents Pre-Clinical Study Results - GlobeNewswire
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Lombard Odier Asset Management USA Corp Has $236,000 Stock Position in V2X, Inc. (NYSE:VVX) - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Market Resilience: Vor Biopharma Inc (VOR) Finishes Weak at 0.83, Down -7.78 - The Dwinnex
Lombard Odier Asset Management Europe Ltd Makes New Investment in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
The Attractiveness of Investing In OmniAb Inc (OABI) is Growing - Knox Daily
Oxford Biomedica Sees Robust Growth in 2024 - TipRanks
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Defense World
Victory Capital Management Inc. Has $991,000 Holdings in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
DCF Advisers LLC Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Shares Cross Below Fifty Day Moving Average of $1.06 - MarketBeat
After epilepsy setback, Ovid charges confidently ahead in CNS - Yahoo Finance
Q3 2025 EPS Estimates for ModivCare Inc. (NASDAQ:MODV) Reduced by Analyst - MarketBeat
Victory Capital Management Inc. Increases Position in OneMain Holdings, Inc. (NYSE:OMF) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Stock Passes Below 50 Day Moving Average of $1.06 - Defense World
Checking in on OmniAb Inc (OABI) after recent insiders movement - Knox Daily
Is OmniAb Inc (OABI) positioned for future growth? - SETE News
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):